CR10440A - Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-yl)etil]amino]metil]fenil]2e-2-propenamida - Google Patents

Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-yl)etil]amino]metil]fenil]2e-2-propenamida

Info

Publication number
CR10440A
CR10440A CR10440A CR10440A CR10440A CR 10440 A CR10440 A CR 10440A CR 10440 A CR10440 A CR 10440A CR 10440 A CR10440 A CR 10440A CR 10440 A CR10440 A CR 10440A
Authority
CR
Costa Rica
Prior art keywords
methyl
indol
hydroxy
phenyl
ethyl
Prior art date
Application number
CR10440A
Other languages
English (en)
Inventor
Murat Acemoglu
Joginder S Bajwa
Karpinski Piotr
Slade Joel
Stowasser Frank
Papoutsakis Dimitris
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10440(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR10440A publication Critical patent/CR10440A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

Se preparan por varios procedimientos formas polimórficas de base libre de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]-metil]fenil]-2E-2-propenamida y sales de la misma.
CR10440A 2006-06-12 2008-11-13 Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-yl)etil]amino]metil]fenil]2e-2-propenamida CR10440A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80451706P 2006-06-12 2006-06-12
US88322407P 2007-01-03 2007-01-03

Publications (1)

Publication Number Publication Date
CR10440A true CR10440A (es) 2011-08-22

Family

ID=38832679

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10440A CR10440A (es) 2006-06-12 2008-11-13 Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-yl)etil]amino]metil]fenil]2e-2-propenamida

Country Status (29)

Country Link
US (1) US7989494B2 (es)
EP (2) EP2086930A2 (es)
JP (3) JP2009540006A (es)
KR (4) KR20160032264A (es)
CN (1) CN102584673B (es)
AR (1) AR061297A1 (es)
AU (1) AU2007257881B2 (es)
BR (1) BRPI0712993A2 (es)
CA (1) CA2650263A1 (es)
CL (1) CL2007001689A1 (es)
CR (1) CR10440A (es)
EA (1) EA017984B1 (es)
EC (1) ECSP088976A (es)
GE (1) GEP20115175B (es)
GT (1) GT200800280A (es)
IL (1) IL195015A (es)
MA (1) MA30511B1 (es)
ME (1) ME00529B (es)
MX (1) MX2008015900A (es)
MY (1) MY149337A (es)
NI (1) NI200800306A (es)
NO (1) NO20090135L (es)
PE (1) PE20080852A1 (es)
PH (2) PH12012501724A1 (es)
SM (1) SMP200900001B (es)
TN (1) TNSN08495A1 (es)
TW (2) TWI515179B (es)
UY (1) UY30406A1 (es)
WO (1) WO2007146716A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ572547A (en) * 2006-06-12 2011-06-30 Novartis Ag SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-yl)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE
AU2008204928B2 (en) * 2007-01-10 2011-03-31 Novartis Ag Formulations of deacetylase inhibitors
WO2017032281A1 (zh) * 2015-08-21 2017-03-02 苏州晶云药物科技有限公司 帕比司他乳酸盐的新晶型
CN106866492B (zh) * 2015-12-10 2021-11-26 江苏豪森药业集团有限公司 帕比司他乳酸盐晶型ii及其制备方法和用途
CN106866491B (zh) * 2015-12-10 2021-12-10 江苏豪森药业集团有限公司 帕比司他乳酸盐晶型ⅰ及其制备方法和用途
WO2018092151A1 (en) * 2016-11-21 2018-05-24 Msn Laboratories Private Limited, R&D Center Process for the preparation of 2-(e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide 2-hydroxypropanoic acid (1:1) and its polymorphs thereof
WO2018163114A1 (en) * 2017-03-10 2018-09-13 Shilpa Medicare Limited Amorphous panobinostat and its lactate salt
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
MX2022001820A (es) * 2019-08-20 2022-03-17 Ono Pharmaceutical Co Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5).
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913122D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
AU2021368107A1 (en) * 2020-10-28 2023-06-22 Viracta Subsidiary, Inc. Hdac inhibitor solid state forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ATE352319T1 (de) 2001-11-06 2007-02-15 Novartis Pharma Gmbh Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
AU2002361022A1 (en) 2001-12-07 2003-06-17 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
MXPA05012464A (es) 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
JP2007501775A (ja) 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
US20080085902A1 (en) 2003-09-23 2008-04-10 Guido Bold Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
NZ572547A (en) 2006-06-12 2011-06-30 Novartis Ag SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-yl)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE

Also Published As

Publication number Publication date
KR20150082690A (ko) 2015-07-15
TNSN08495A1 (en) 2010-04-14
SMAP200900001A (it) 2009-01-14
CA2650263A1 (en) 2007-12-21
EA017984B1 (ru) 2013-04-30
MX2008015900A (es) 2009-03-06
ECSP088976A (es) 2009-01-30
IL195015A0 (en) 2009-08-03
PH12012501724A1 (en) 2014-05-12
KR20090015968A (ko) 2009-02-12
WO2007146716A2 (en) 2007-12-21
MA30511B1 (fr) 2009-06-01
PE20080852A1 (es) 2008-08-19
CL2007001689A1 (es) 2008-05-16
BRPI0712993A2 (pt) 2012-04-17
ME00529B (me) 2011-10-10
NO20090135L (no) 2009-03-12
US7989494B2 (en) 2011-08-02
MY149337A (en) 2013-08-30
AR061297A1 (es) 2008-08-20
JP2009540006A (ja) 2009-11-19
TW201441190A (zh) 2014-11-01
GEP20115175B (en) 2011-03-10
UY30406A1 (es) 2008-01-31
EA200802383A1 (ru) 2010-02-26
AU2007257881B2 (en) 2011-06-16
WO2007146716A3 (en) 2009-07-30
EP2409967A1 (en) 2012-01-25
JP2015164968A (ja) 2015-09-17
GT200800280A (es) 2015-11-24
CN102584673B (zh) 2014-08-06
NI200800306A (es) 2012-02-01
SMP200900001B (it) 2010-03-01
JP2013139476A (ja) 2013-07-18
CN102584673A (zh) 2012-07-18
US20090192210A1 (en) 2009-07-30
KR20160032264A (ko) 2016-03-23
TWI453196B (zh) 2014-09-21
TWI515179B (zh) 2016-01-01
KR20140142335A (ko) 2014-12-11
IL195015A (en) 2014-03-31
EP2086930A2 (en) 2009-08-12
AU2007257881A1 (en) 2007-12-21
PH12012501725A1 (en) 2015-07-06
TW200815344A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
CR10440A (es) Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-yl)etil]amino]metil]fenil]2e-2-propenamida
CR10439A (es) Sales de n-hidroxi-3-[4-[[[2-(metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
ECSP088957A (es) Composición farmacéutica estable que contiene docetaxel y método para su fabricación
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
DOP2008000068A (es) Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
CU20080237A7 (es) Polimorfos de n-hidroxi-3-[4-[[[2-metil-1h-indol-3-il)etil]amino]metil]fenil]2e-2-propenamida
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
ECSP088978A (es) Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma
HN2008001862A (es) Polimorfos de n-hodroxi-3 [4-[[[2-metil-1h-indol-3-il)etil]amino] metil]fenil]-2e-2-2propenamida

Legal Events

Date Code Title Description
FC Refusal